SCHEMBL6794094

SCHEMBL6794094

CC(C)(C)OC(=O)Nc1nc(CCN(C(=O)OC(C)(C)C)c2ccc(NC(=O)c3ccccc3-c3ccc(Cl)cc3)cc2)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.39
MAPT P10636 3/20 0.37
SREBF2 Q12772 1/20 0.37
ATM Q13315 1/20 0.37
SIRT1 Q96EB6 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
BAP1 Q92560 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
SMO Q99835 2/20 0.35
CYP1A2 P05177 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6795163 0.93 KMT2A (0.38) MAPTSREBF2SIRT1MEN1KMT2A
SCHEMBL6788744 0.92 NPC1 (0.41) MAPTSREBF2SIRT1ALDH1A1LMNA
SCHEMBL6795504 0.91 MTTP (0.42) MAPTSIRT1SMOTP53
SCHEMBL6490015 0.91 GCGR (0.41) CCR2MAPTSREBF2MEN1KMT2A
SCHEMBL6499352 0.91 MAPT (0.39) CCR2MAPTSREBF2MEN1KMT2A
SCHEMBL6794499 0.88 CYP3A4 (0.40) MAPTSREBF2SIRT1MEN1KMT2A
SCHEMBL6793968 0.87 GAA (0.48) MAPTSREBF2MEN1KMT2AALDH1A1
SCHEMBL6788594 0.87 NPC1 (0.43) MAPTSREBF2SIRT1MEN1KMT2A
SCHEMBL6497778 0.86 SREBF2 (0.38) CCR2MAPTSREBF2SIRT1MEN1
SCHEMBL6491334 0.86 GCGR (0.43) CCR2MAPTSREBF2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 CCR2 799/4885MAPT 4795/4885SREBF2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.